Cas:1192035-51-0 N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline manufacturer & supplier

Chemical Name:N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline

CAS.NO:1192035-51-0

Synonyms:4-Bromo-N,N-bis[4-[(2-ethylhexyl)oxy]phenyl]benzenamine;4-bromo-N,N-bis((4-(2-ethyl)hexyloxy)phenyl)aniline;X4478

Molecular Formula:C₃₄H₄₆BrNO₂

Molecular Weight:580.63900

HS Code:2922199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:21.70000

Exact Mass:579.27100

LogP:11.10930

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Bromo-N,N-bis[4-[(2-ethylhexyl)oxy]phenyl]benzenamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,X4478 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,X4478 Use and application,4-Bromo-N,N-bis[4-[(2-ethylhexyl)oxy]phenyl]benzenamine technical grade,usp/ep/jp grade.

Related News: Javier Valero-Elizondo, M.D., M.P.H., from the Houston Methodist DeBakey Heart and Vascular Center in Texas, and colleagues compared FT for individuals with ASCVD only, cancer only, both ASCVD and cancer, and neither ASCVD nor cancer using data from the National Health Interview Survey. N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline manufacturer In the context of increasingly tight global productive capacity cooperation in the pharmaceutical industry, some multinational pharmaceutical companies have chosen to abandon their original full industrial chain model and shift their focus to market operations. R & D, clinical, and production links reduce costs through outsourcing. Patented APIs came into being. N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline supplier A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline vendor The pharmaceutical industry is related to the national economy and the people’s livelihood. The entire upstream and downstream areas involve all aspects of the national economy. Our government has a long-term direct or indirect policy preference for this. N-(4-bromophenyl)-4-(2-ethylhexoxy)-N-[4-(2-ethylhexoxy)phenyl]aniline factory The on-body wear is similar to that of an insulin pump. Unlike insulin pump therapy, however, the investigational system is designed such that users enter only their body weight for the iLet to initialize therapy.